Challenges in drug development for muscle disease: A stakeholders' meeting
- 14 December 2006
- journal article
- Published by Wiley in Muscle & Nerve
- Vol. 35 (1), 8-16
- https://doi.org/10.1002/mus.20686
Abstract
Current treatment benefits for patients with muscle disease are limited, but progress in legislative and scientific initiatives have set the stage for the development of new therapies. The MD‐CARE Act (Public Law 107‐84), which allocates federal resources to muscular dystrophy, was approved by Congress and signed into law by the President of the United States in 2001. This has shifted the emphasis toward translational research. To facilitate a push toward therapy for muscle disorders, the Muscular Dystrophy Association (MDA) sponsored a meeting with representatives from industry, the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and other government agencies and academia. Each contributed in different ways. The FDA helped define the necessary data to support investigational new drug (IND) applications including the design of proof‐of‐principle studies, outcome measures for clinical trials, and the pathway for developing surrogate measures for fast‐tracking promising new drugs. The NIH, other government agencies, and the MDA described potential funding sources for translational research. Industry delineated a complementary role with academia, and academic investigators elucidated the current strengths and weaknesses of available clinical endpoints. The meeting provided a format for communication for diverse disciplines that usually have no common meeting ground, helping to lay the foundation for bringing products to market in a timely fashion. Muscle Nerve, 2006Keywords
This publication has 39 references indexed in Scilit:
- Cardiovascular Health Supervision for Individuals Affected by Duchenne or Becker Muscular DystrophyPublished by American Academy of Pediatrics (AAP) ,2005
- Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotideThe Journal of Gene Medicine, 2005
- CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophyAnnals of Neurology, 2005
- Myostatin, a negative regulator of muscle mass: implications for muscle degenerative diseasesCurrent Opinion in Pharmacology, 2005
- Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon SkippingScience, 2004
- Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cellsGene Therapy, 2004
- Development of a disease-specific disability instrument for Pompe diseasePediatric Rehabilitation, 2003
- Duchenne Muscular DystrophyAmerican Journal of Physical Medicine & Rehabilitation, 1995
- Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular DystrophyNew England Journal of Medicine, 1989
- Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individualsCell, 1987